Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amgen
(NQ:
AMGN
)
332.45
+2.30 (+0.70%)
Streaming Delayed Price
Updated: 12:52 PM EDT, Jul 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amgen
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
43
44
Next >
Analyst Ratings for Amgen
October 31, 2022
Amgen (NASDAQ:AMGN) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
October 31, 2022
Upgrades
Via
Benzinga
What 6 Analyst Ratings Have To Say About Amgen
October 31, 2022
Amgen (NASDAQ:AMGN) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Will Chart Analysts Notice Bad Omen on Amgen's Chart
October 20, 2022
If history is any guide, there may be trouble ahead for shares of Amgen (NASDAQ:AMGN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
Via
Benzinga
Is Amgen Stock a Buy Now?
October 20, 2022
A recent analyst upgrade has boosted the stock.
Via
The Motley Fool
Expert Ratings for Amgen
October 11, 2022
Amgen (NASDAQ:AMGN) has observed the following analyst ratings within the last quarter:
Via
Benzinga
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
October 31, 2022
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.
Via
TheNewswire.com
Exposures
Product Safety
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
October 31, 2022
By Mark Gilman, Benzinga
Via
News Direct
Exposures
Product Safety
Dogs Of The Dow: A Leading Strategy In 2022
October 30, 2022
At that time the Dow Dogs strategy had a positive year-to-date return versus the negative return of the Dow Jones Industrial Average Index and the S&P 500 Index.
Via
Talk Markets
Could Amgen Continue To Soar In This Bear Market?
October 28, 2022
Amgen did a mini pull back then broke out on 24 Oct and committed above $260. According to the Wyckoff trading method, there is no immediate threatening supply hence the price could continue to climb...
Via
Talk Markets
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
October 27, 2022
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.
Via
Benzinga
Why Amgen Is Up More Than 6% Today
October 11, 2022
An upgrade highlights one of the more philosophical reasons you want to bet on this biopharma name right now.
Via
The Motley Fool
Dissecting The Dow Jones Industrial Average: Half Empty Or Half Full?
October 26, 2022
The Dow Jones Industrial Average is a leading index comprised of 30 stocks. Consequently, it has long been considered a great proxy for the stock market at large.
Via
Talk Markets
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
October 25, 2022
The company hopes to come out next year with at least one heart-failure drug.
Via
Investor's Business Daily
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?
October 25, 2022
Biosimilars are bringing down prescription drug costs without sacrificing quality.
Via
The Motley Fool
Here's How Much You Would Have Made Owning Amgen Stock In The Last 20 Years
October 21, 2022
Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 1.09% on an annualized basis producing an average annual return of 8.55%. Currently, Amgen has a market capitalization of...
Via
Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
October 20, 2022
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Via
Investor's Business Daily
Merck Nears Breakout Point After October Surprise Good News
October 19, 2022
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
10 Health Care Stocks Whale Activity In Today's Session
October 18, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
2 Top Healthcare Stocks to Buy for the Long Haul
October 18, 2022
These biotech companies have a long ramp of revenue growth ahead.
Via
The Motley Fool
MarketBeat: Week in Review 10/10-10/14
October 15, 2022
A volatile week is ending with the market moving lower. Here are some of the stories the MarketBeat analysts were covering this week.
Via
MarketBeat
Exposures
COVID-19
Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts
October 14, 2022
Via
Benzinga
Amgen Shares Leap Higher On Upbeat Outlook For Obesity Treatment
October 13, 2022
Shares of Amgen soared 5.72% Tuesday and added to those gains Wednesday. The gap-up followed a Morgan Stanley upgrade and increase to the price target.
Via
MarketBeat
Dividend Income Update September 2022
October 13, 2022
With the start of the final quarter of 2022, it’s time to take a look back at my previous month of dividend income.
Via
Talk Markets
Amgen Stock Shows Market Leadership With Jump To 90 RS Rating
October 12, 2022
On Wednesday, Amgen stock hit a key technical milestone, with its Relative Strength Rating upgraded to 90, a rise from 78 the day before.
Via
Investor's Business Daily
What 6 Analyst Ratings Have To Say About Amgen
October 12, 2022
Over the past 3 months, 6 analysts have published their opinion on Amgen (NASDAQ:AMGN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's...
Via
Benzinga
4 Biotech Stocks With Huge Incoming Catalysts
October 12, 2022
All four of these drugmakers are expecting important FDA approval decisions over the next few months.
Via
The Motley Fool
Biotech Stocks Well-Positioned For The Fourth Quarter
October 12, 2022
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.
Via
Talk Markets
Analyst Ratings for Amgen
October 11, 2022
Over the past 3 months, 5 analysts have published their opinion on Amgen (NASDAQ:AMGN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's...
Via
Benzinga
Amgen, The Big Name You Need To Know Going Up Against Novo, Lilly In Obesity
October 11, 2022
One analyst says a coming-from-behind obesity player could differentiate itself.
Via
Investor's Business Daily
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
43
44
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.